Detalhe da pesquisa
1.
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open-label study.
Am J Hematol
; 97(7): E226-E229, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35384026
2.
One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.
Blood Adv
; 7(24): 7539-7550, 2023 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37934880